Image

Investigating EEG as a Biomarker for Tinnitus Improvement After Bimodal Stimulation

Investigating EEG as a Biomarker for Tinnitus Improvement After Bimodal Stimulation

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The aim of the proposed study is to investigate the use of resting-state Electroencephalogram (EEG)-Based Brain Entropy (EBDBE) and auditory brainstem responses (ABR) as an objective measure of tinnitus improvement following the use of a bimodal stimulation device in individuals with tinnitus after six weeks of bi-modal stimulation.

Eligibility

Treatment Group Inclusion Criteria:

  • 18 years and over at time of consent
  • Ability to read and understand English
  • Willing and able to provide and understand informed consent
  • Willing to commit to the full duration of the investigation
  • Subjective tinnitus
  • Tinnitus duration of greater than or equal to 3 months and less than or equal to 20 years at time of consent (only for participants in treatment group)
  • Baseline THI score from 40 to 76 (only for participants in treatment group)
  • Hearing loss condition - can hear the acoustic stimulation of the Lenire device (only for participants in treatment group)

Treatment Group Exclusion Criteria:

  • Subjective tinnitus, where pulsatility is the dominant feature (only for participants in treatment group)
  • Objective tinnitus
  • Can't hear acoustic stimulation of the Lenire device within its mid- range volume setting
  • Began wearing hearing aids within the past 3 months
  • A healthcare provider has diagnosed Meniere's disease or another disorder associated with fluctuating hearing loss.
  • History of auditory hallucinations
  • Tumor on the hearing or balance nervous systems
  • Hospitalization, or visit to a physician, for a head or neck injury, including whiplash, in the previous 12 months
  • Initiated new prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Ceased prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Changed dosage of prescription medications in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Any use of benzodiazepines or sedative hypnotics (either regularly or on demand)
  • Neurological condition that may lead to seizures or loss of consciousness (e.g., epilepsy)
  • Participant with a pacemaker or other electro-active implanted device
  • Participant previously diagnosed with psychosis or schizophrenia
  • Participants diagnosed with Burning Mouth Syndrome
  • A diagnosis of bothersome temporomandibular joint disorder (TMJ) has been rendered
  • Previous involvement in a clinical investigation for tinnitus treatment or had an implantable or surgical intervention for tinnitus
  • Inability to physically or comprehensively use the device
  • Oral piercings that cannot or will not be removed
  • Pregnancy per patient report
  • Prisoner
  • PI does not deem the candidate to be suitable for the investigation for other reasons not listed above. Rationale must be provided.

Control Group Inclusion Criteria:

  • 18 years and over at time of consent
  • Ability to read and understand English
  • Willing and able to provide and understand informed consent
  • Willing to commit to the full duration of the investigation

Control Group Exclusion Criteria:

  • Began wearing hearing aids within the past 3 months
  • Hospitalization, or visit to a physician, for a head or neck injury, including whiplash, in the previous 12 months
  • Initiated new prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Ceased prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Changed dosage of prescription medications in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics.
  • Any use of benzodiazepines or sedative hypnotics (either regularly or on demand)
  • Neurological condition that may lead to seizures or loss of consciousness (e.g., epilepsy)
  • Participant previously diagnosed with psychosis or schizophrenia
  • A diagnosis of bothersome temporomandibular joint disorder (TMJ) has been rendered
  • Prisoner
  • PI does not deem the candidate to be suitable for the investigation for other reasons not listed above. Rationale must be provided.

Study details
    Tinnitus

NCT07158034

University of Minnesota

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.